rs7508

This is a 3 prime utr variant variant in the ASAH1 gene.

GWAS Catalog Trait Associations (2)

Genome-wide significant associations (p < 5×10⁻⁸) from the NHGRI-EBI GWAS Catalog.

triglyceride measurement

Koskeridis F et al. Pleiotropic genetic architecture and novel loci for C-reactive protein levels. Nature Communications 13(1):6939 (2022)
Allele A
OR 0.02
p 5.0e-8
N 361,194
Large GWAS
European

atrial fibrillation

Allele A
OR 0.06
p 1.0e-48
N 1,840,341
Large GWAS
European
Allele A
OR 1.07
p 1.0e-44
N 1,650,345
Meta-analysisLarge GWAS
multi-ancestry
Allele A
OR 0.01
p 2.0e-20
N 1,486,094
Large GWAS
European
Allele A
OR 1.07
p 2.0e-21
N 1,030,836
Large GWAS
European
Allele A
OR 0.01
p 1.0e-20
N 1,030,836
Large GWAS
European
Roselli C et al. Multi-ethnic genome-wide association study for atrial fibrillation. Nature Genetics 50(9):1225-1233 (2018)
Allele A
OR 1.07
p 2.0e-19
N 588,190
Large GWAS
multi-ancestry
Allele A
OR 1.10
p 6.0e-10
N 118,755
Large GWAS
European

ClinVar annotation

Benign☆☆☆
2 submitters1 publication

Farber lipogranulomatosis (FRBRL)

View on ClinVar →

About ASAH1

This gene encodes a member of the acid ceramidase family of proteins. Alternative splicing results in multiple transcript variants, at least one of which encodes a preproprotein that is proteolytically processed. Processing of this preproprotein generates alpha and beta subunits that heterodimerize to form the mature lysosomal enzyme, which catalyzes the degradation of ceramide into sphingosine and free fatty acid. This enzyme is overexpressed in multiple human cancers and may play a role in cancer progression. Mutations in this gene are associated with the lysosomal storage disorder, Farber lipogranulomatosis, and a neuromuscular disorder, spinal muscular atrophy with progressive myoclonic epilepsy. [provided by RefSeq, Oct 2015]

View all ASAH1 variants →

Gene information from NCBI Gene. Variant classifications from ClinVar.

Community Wiki

No community notes yet for this variant. Sign in to start one.

Comments

Sign in to join the discussion.

Loading comments…